



# Università degli Studi di Ferrara

INFORMAZIONI  
PERSONALI

Anna Rizzi

✉ [a.rizzi@unife.it](mailto:a.rizzi@unife.it)

POSIZIONE PER LA QUALE SI  
CONCORRE

ESPERIENZA  
PROFESSIONALE

---

RTD, Dept. Medical Sciences, Section of Pharmacology, University of Ferrara (2 May 2012 - 1 May 2016).

Research Associate on a collaborative project between Prof G. Calo and Allergan financed by Allergan (January 2009 – November 2011).

Research Associate on a collaborative project between Prof D. Regoli and Prof D., Kapusta financed by the National Institutes of Health (collaborative grant NHLBI HL-71212) (January 2004 – December 2008).

Research Associate for Institute of Biotechnology Research S.r.l. (I.R.B.), Altavilla Vicentina (Vicenza), Italy. (June 2003 – December 2003)

Research Fellow (assegnista). Department of Experimental and Clinical Medicine, Section of Pharmacology, University of Ferrara, Italy. (May 1999 – May 2003)

PhD Student in “Cellular and Molecular Pharmacology” Tutor: Prof. Domenico Regoli. Department of Experimental and Clinical Medicine, Section of Pharmacology, University of Ferrara, Italy (1995 – 1998).

Research Fellow at the UCSF. Prof. N. Bunnett, Department of Physiology, University of San Francisco, USA. (Borsa di studio assegnata dal Consiglio Nazionale delle Ricerche nell’ambito di: International exchange “Short-term mobility” CNR Prot. 055366) (July – September 1997).

Research Fellow. Department de Pharmacologie, Faculte' de Medecine, Universite' de Sherbrooke (Quebec) Canada. (June - December 1994).

Associate Professorship – in February 2014 Dr A Rizzi has been qualified for associate professorship by the pharmacology national ASN committee (Bando 2012 – 05/G1 Farmacologia Clinica e Farmacognosia).

Chief Executive Officer spin off UFPeptides s.r.l. (Genuary 2007- December 2012)

#### ISTRUZIONE E FORMAZIONE

---

19 January 1999, *PhD* in “Cellular and Molecular Pharmacology” Title of the thesis: “Pharmacological characterisation of kinin receptors in different species”. Tutor: Prof. D Regoli

March 1995, Esame di stato per l’abilitazione alla professione di farmacista

*Degree in Pharmaceutical Chemistry and Technology, Faculty of Pharmacy*, 16 March 1994, University of Ferrara, Italy. Score: 110/110 cum laude. Experimental thesis: “GABA release from different guinea pig brain areas in vitro: effect of 5-HT”.

*Maturity Degree*, July 1986, Liceo Scientifico Statale "P. Paleocapa", Rovigo, Italy. Score 50/60.

#### COMPETENZE PERSONALI

---

Lingua madre Italiano

Inglese ottimo livello sia scritto che parlato

Anna Rizzi has a large experience in research with a broad background in the pharmacology of peptidergic systems. Since 1996 A. Rizzi has published 93 papers (number of citations 4047, H number 35) focused on peptide receptor pharmacology in particular in the fields of kinins, tachykinins, endothelins, opioids, nociceptin/orphanin FQ, urotensin II and, more recently, neuropeptide S. Several of these papers, particularly in the field of nociceptin/orphanin FQ and neuropeptide S, have been highly quoted placing them in the top 1% within their field: according to essential science indicators this demonstrated that the work summarized in those papers was highly influential and made a significant impact among scientists working in the field. These scientific results allowed us to establish a series of collaborations with other group of research at local (Remo Guerrini on peptide medicinal chemistry, Michele Morari on neurochemistry studies, Paolo Zamboni and Gioacchino Mollica, pharmacological characterization of GPCR in human tissues), at national (Maurizio Massi and Roberto Ciccocioppo, Camerino, food intake studies; Lia Di Giannuario, Roma, pain and morphine tolerance), European (Dave Lambert, Leicester UK, cellular pharmacology studies; Ulrich Zeihofer, Erlangen DE, spinal analgesia), and internationals level (Jeff Mogil, Montreal, Canada, N/OFQ and stress induced analgesia; Dan Kapusta, New Orleans, US, N/OFQ and renal functions). In addition, Anna Rizzi substantially contributed to the development of several industrial projects performed in collaboration with Menarini, Italfarmaco, the Institute of Biotechnology Research, NiKem, Zealand Pharma, Aventis, Sanofi, Schering, Rottapharm, GlaxoSmithKline, Allergan and Helsin.

Patente di guida patente B

ULTERIORI INFORMAZIONI

---

Allego al presente documento CV completo di pubblicazioni, grants ed attività didattica

▪

ALLEGATI

---

Il sottoscritto acconsente, ai sensi del D.Lgs. 30/06/2003 n.196, al trattamento dei propri dati personali.

Il sottoscritto acconsente alla pubblicazione del presente curriculum vitae sul sito dell'Università di Ferrara.

FIRMA

 Anna Rizzi

## **Rizzi Anna**

### ***Publications***

Dati bibliometrici

93 articoli scientifici di cui 21 come primo autore.

4047 citazioni

H index 35

### ***Full Papers***

1. Gobeil F, Pheng L H, Badini I, Nguyenle X K, Pizard A, **Rizzi A**, Blouin D, and Regoli D. Receptors for kinins in the human isolated umbilical vein. *Br J Pharmacol* 118 (2): 289-294, 1996.
2. Bogoni G, **Rizzi A**, Calò G, Campobasso C, D'Orleans-Juste P, and Regoli D. Characterization of endothelin receptors in the human umbilical artery and vein. *Br J Pharmacol* 119: 1600-1604, 1996.
3. Regoli D, Calò G, **Rizzi A**, Bogoni G, Gobeil F, Campobasso C, Mollica G, and Beani L. Bradykinin receptors and receptor ligands (with special emphasis on vascular receptors). *Regul Peptides* 65: 83-89, 1996.
4. Calò G, **Rizzi A**, Bogoni G, Neugebauer V, Salvadori S, Guerrini R, Bianchi C, and Regoli D. The mouse vas deferens: a pharmacological preparation sensitive to nociceptin. *Eur J Pharmacol* 311 (1): R3-5, 1996.
5. Calò G, **Rizzi A**, Traina L, and Regoli D. Pharmacological characterization of a vasopressin V1 receptor in the isolated human gastric artery. *Life Sci* 60: PL63-68, 1997.
6. Regoli D, **Rizzi A**, Calò G, Nsa Allogho S, and Gobeil F. B1 and B2 kinin receptors in various species. *Immunopharmacol* 36: 143-147, 1997.
7. **Rizzi A**, Gobeil F, Bogoni G, Calò G, Campobasso C, Inamura N, and Regoli D. Antagonistic effects of FR 173657 on human, pig, rabbit and guinea pig kinin receptors. *Can J Physiol Pharmacol* 75: 601-608, 1997.
8. **Rizzi A**, Gobeil F, Calò G, Inamura N, and Regoli D. FR 173657, a new potent and selective non peptide kinin B2 receptor antagonist: an in vitro study. *Hypertension* 29: 951-956, 1997.
9. Calò G, **Rizzi A**, Bodin M, Neugebauer W, Salvadori S, Guerrini R, Bianchi C, and Regoli D. Pharmacological characterization of nociceptin receptor: an in vitro study. *Can J Physiol Pharmacol* 75 (6): 713-8, 1997.
10. Guerrini, R, Calò G, **Rizzi A**, Bianchi C, Lazarus L H, Salvadori S, Temussi PA, and Regoli D. Address and message sequences for the nociceptin receptor: a structure- activity study of nociceptin-(1-13)-peptide amide. *J Med Chem* 40 (12): 1789-93, 1997.
11. Regoli D, **Rizzi A**, and Calò G. Pharmacology of the kallikrein-kinin system. *Pharmacol Res* 35 (6): 513-5, 1997.
12. **Rizzi A**, Calò G, Amadesi S, and Regoli D. Kinin B1 and B2 receptors in pig vessels: characterization of two monoreceptor systems. *N S Arch Pharmacol* 356: 662-670, 1997.
13. Gessi S, **Rizzi A**, Calò G, Agnello G, Jorizzo G, Mollica G, Borea P A, and Regoli D. Human vascular kinin receptors of the B2 type characterized by radioligand binding. *Br J Pharmacol* 122 (7): 1450-4, 1997
14. **Rizzi A**, Calò G, Battistini B, and Regoli D. Contractile activity of endothelins and their precursors in human umbilical artery and vein: identification of distinct endothelin-converting enzyme activities. *J Cardiovasc Pharmacol* 31 (1): S58-61, 1998.
15. Guerrini R, Calò G, **Rizzi A**, Bigoni R, Bianchi C, Salvadori S, and Regoli D. A new selective antagonist of the nociceptin receptor. *Br J Pharmacol* 123 (2): 163-5, 1998.
16. Calò G, Guerrini R, Bigoni R, **Rizzi A**, Bianchi C, Regoli D, and Salvadori, S. Structure-Activity Study of the Nociceptin(1-13)-NH<sub>2</sub> N-Terminal Tetrapeptide and Discovery of a Nociceptin Receptor Antagonist. *J Med Chem* 41 (18): 3360-6, 1998.
17. Regoli D, Nsa Allogho S, **Rizzi A**, and Gobeil FJ. Bradykinin receptors and their antagonists. *Eur J Pharmacol* 348 (1): 1-10, 1998.

18. Calò G, **Rizzi A**, Marzola G, Guerrini R, Salvadori S, Beani L, Regoli D, and Bianchi C. Pharmacological characterization of the nociceptin receptor mediating hyperalgesia in the mouse tail withdrawal assay. *Br J Pharmacol* 25(2):373-8, 1998.
19. **Rizzi A**, Quaglio D, Vasquez G, Mascoli F, Amadesi S, Calò G, Regoli D, and Zamboni P. Effects of vasoactive agents in healthy and diseased saphenous veins. *J Vasc Surgery* 28: 855-861, 1998.
20. Varani K, Calò G, **Rizzi A**, Merighi S, Toth G, Guerrini R, Salvadori S, Borea PA, and Regoli D. Nociceptin receptor binding in mouse forebrain membranes: thermodynamic characteristics and structure activity relationships. *Br J Pharmacol* 125: 1485-1490, 1998.
21. Bigoni R, Giuliani S, Calò G, **Rizzi A**, Guerrini R, Salvadori S, Regoli D and Maggi CA. Characterization of nociceptin receptors in the periphery: in vitro and in vivo studies. *Naunyn Schmiedebergs Arch Pharmacol* 359(3):160-7, 1999.
22. **Rizzi A**, Trevisani M, Tognetto M, Calò G, Fabbri L, Mapp C, Guerrini R, Salvadori S, Regoli D. and Geppetti P. Nociceptin receptor activation inhibits tachykinergic non adrenergic non cholinergic contraction of guinea pig isolated bronchus. *Life Science* 64(13):PL157-63, 1999.
23. **Rizzi A**, Rizzi C, Amadesi S, Calò G, Varani K, Inamura N, Regoli D. Pharmacological characterisation of the first non-peptide bradykinin B2 receptor agonist FR 190997: an in vitro study on human, rabbit and pig vascular B2 receptors. *Naunyn Schmiedebergs Arch Pharmacol* 360:361-7, 1999.
24. Meini S, Quartara L, **Rizzi A**, Patacchini R, Cucchi P, Giolitti A, Calò G, Regoli D, Criscuoli M, Maggi CA. MEN 11270, A novel selective constrained peptide antagonist with high affinity at the human B2 kinin receptor. *J Pharmacol Exp Ther* 289:1250-6, 1999.
25. **Rizzi A**, Bigoni R, Calò G, Guerrini R, Salvadori S, Regoli D. [Nphe(1)]nociceptin-(1-13)-NH(2) antagonizes nociceptin effects in the mouse colon. *Eur J Pharmacol* 385(2-3):R3-5, 1999.
26. Rizzi C, **Rizzi A**, Calò G, Jorizzo G, Agnello G, Mollica G, Inamura N, Regoli D: Characterization of FR 172357, a new non-peptide bradykinin B(2) receptor antagonist, in human, pig and rabbit preparations. *Eur J Pharmacol*, 386(1):25-31, 1999.
27. Varani K, **Rizzi A**, Calò G, Bigoni R, Toth G, Guerrini R, Gessi S, Salvadori S, Borea PA, Regoli D. Pharmacology of [Tyr1]nociceptin analogs: receptor binding and bioassay studies. *Naunyn Schmiedebergs Arch Pharmacol* 360:270-7, 1999.
28. Bigoni R, Calò G, **Rizzi A**, Guerrini R, De Risi C, Hashimoto Y, Hashiba Y, Lambert DG, and Regoli D. In vitro characterization of J-113397 a non peptide nociceptin/orphanin FQ receptor antagonist. *Naunyn Schmiedebergs Arch Pharmacol*, 361:565-8,2000.
29. Bigoni R, **Rizzi A**, Rizzi D, Becke JA, Kieffer BL, Simonin F, Regoli D, and Calò G. In vitro pharmacological profile of peptide III-BTD a novel ligand for nociceptin/orphanin FQ and opioid receptors. *Life Sciences*, 68(2): 233-239, 2000.
30. Calò G, Guerrini R, Bigoni R, **Rizzi A**, Marzola G, Okawa H, Bianchi C, Lambert G, Salvadori S, and Regoli D. Characterization of [Nphe1]NC(1-13)NH2, a new selective nociceptin receptor antagonist. *Br J Pharmacol*, 129: 1183-1193, 2000.
31. Calò G, Guerrini R, **Rizzi A**, Salvadori S, and Regoli D. Pharmacology of nociceptin and its receptor. A novel therapeutic target . Review, *Br J Pharmacol*, 129:1261-83, 2000.
32. Calò G, Bigoni R, **Rizzi A**, Guerrini R, Salvadori S, and Regoli D. Nociceptin/orphanin FQ receptor ligands. *Peptides*, 21(7) 935-947, 2000.
33. Guerrini R, Calò G, Bigoni R, **Rizzi A**, Varani K, Toth G, Gessi S, Hashibita E, Hashimoto Y, Lambert DG, Borea PA, Tomatis R, Salvadori S, and Regoli D. Further studies on nociceptin-related peptides: discovery of a new chemical template with antagonistic activity on the nociceptin receptor. *J Med Chem* 43(15): 2805-13, 2000.
34. Guerrini R, Calò G, **Rizzi A**, Bigoni R, Rizzi D, Regoli D, and Salvadori S: Structure-activity relationships of nociceptin and related peptides: comparison with dynorphin A. *Peptides* 21(7): 923-933, 2000.
35. Quartara L, Ricci R, Meini S, Patacchini R, Giolitti A, Amadesi S, Rizzi C, **Rizzi A**, Varani K, Borea PA, A Maggi C, Regoli D.: Ala scan analogues of HOE 140. Synthesis and biological activities. *Eur J Med Chem. Nov*;35(11):1001-10, 2000.
36. **Rizzi A**, Bigoni R, Marzola G, Guerrini R, Salvadori S, Regoli D, and Calò G. The nociceptin/orphanin FQ receptor antagonist, [Nphe1]NC(1-13)NH2, potentiates morphine analgesia. *Neuroreport* 11(11): 2369-72, 2000.

37. **Rizzi A**, Bigoni R, Marzola G, Guerrini R, Salvadori S, and Regoli D. Characterisation of the locomotor activity inhibiting effect of nociceptin/orphanin FQ in mice. *Naunyn Schmiedebergs Arch Pharmacol*, 363: 161-165, 2001
38. Rizzi D, Bigoni R, **Rizzi A**, Jenke F, Wichmann J, Guerrini G, Regoli D, and Calo' G: Effects of Ro 64-6198 in nociceptin/orphanin FQ-sensitive isolated tissues. *Naunyn Schmiedebergs Arch Pharmacol*, 363, 551-555, 2001
39. **Rizzi A**, Marzola G, Bigoni R, Guerrini R, Salvadori S, Mogil JS, Regoli D, and Calò G: Endogenous nociceptin signaling and stress-induced analgesia, *Neuroreport*, 12 (14), 2001
40. Regoli D, Rizzi A, Perron SI, and Gobeil F. Classification of kinin receptors. *Biol. Chem.* 382: 31-35, 2001
41. Guerrini R, Calò G, Bigoni R, Rizzi D, **Rizzi A**, Zucchini M, Varani K, Hashiba E, Lambert DG, Toth G, Borea PA, Salvadori S, and Regoli D. Structure-activity studies of the Phe4 residue of nociceptin(1-13)-NH<sub>2</sub>: identification of highly potent agonists of the nociceptin/orphanin FQ receptor. *J Med Chem*, 44 (23): 3956-3964, 2001.
42. Di Giannuario A, **Rizzi A**, Pieretti S, Guerrini R, Bertorelli R, Salvadori S, Regoli D, and Calò G. Further studies on the antinociceptive effect of [Nphe1]NC(1-13)NH<sub>2</sub> in mice. *Neurosci Lett*, 316: 25-28, 2001
43. Camarda V, **Rizzi A**, Calò G, Gendrom G, Perron S, Kostenis E, Zamboni P, Mascoli F, and Regoli D. Effects of human urotensin II in isolated vessels of various species. *NS Archives of Pharmacology*, 365: 141-149, 2002
44. Camarda V, **Rizzi A**, Calo G, Guerrini R, Salvadori S, Regoli D. Pharmacological profile of hemokinin 1: a novel member of the tachykinin family. *Life Sci* 71(4):363-370, 2002
45. Camarda V, **Rizzi A**, Calo G, Wirth K, Regoli D. Pharmacological characterisation of novel kinin B2 receptor ligands. *Can J Physiol Pharmacol* 80(4):281-286, 2002
46. Camarda V, Guerrini R, Kostenis E, **Rizzi A**, Calò G, Hattemberg A, Salvadori S, and Regoli D. A new selective ligand for the urotensin II receptor. *Br J Pharmacol*, 137(3):311-314, 2002.
47. Bigoni R, Calo G, **Rizzi A**, Okawa H, Regoli D, Smart D, Lambert DG. Effects of naloxone benzoylhydrazone on native and recombinant nociceptin/orphanin FQ receptors. *Can J Physiol Pharmacol* 80(5):407-412, 2002
48. Bigoni R, Rizzi D, **Rizzi A**, Camarda V, Guerrini R, Lambert DG, Hashiba E, Berger H, Salvadori S, Regoli D, Calo' G. Pharmacological characterization of (pX)Phe4]nociceptin(1-13)amide analogues: I) in vitro studies. *NS Archives of Pharmacology*, 365: 442-449, 2002.
49. Meini S, Lecci A, Carini F, Tramontana M, Giuliani S, Maggi CA, Ricci R, Fabbri G, Anichini B, Harmat N, **Rizzi A**, Camarda V, Regoli D, Quartara L In vitro and in vivo activity of analogues of the kinin B2 receptor antagonist MEN 11270. *Can J Physiol Pharmacol* 80 (4): 293-302, 2002
50. Rizzi D, **Rizzi A**, Bigoni, R, Camarda V, Marzola G, Guerrini R, De Risi C, Regoli D, and Calò G. [Arg14,Lys15]nociceptin, a highly potent antagonist of the nociceptin/orphanin FQ receptor: in vitro and in vivo studies, *J Pharmacol Exp Ther*, 300: 57-63, 2002
51. Calo' G, **Rizzi A**, Rizzi D, Bigoni R, Guerrini R, Marzola G, Marti M, McDonald J, Morari M, Lambert D, Salvadori S, and Regoli D. [Nphe1,Arg14,Lys15]nocicerin-NH<sub>2</sub>, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor. *Br. J. Pharmacol*, 136: 303-311, 2002
52. Calo' G, **Rizzi A**, Bigoni R, Guerrini R, Salvadori S, Regoli D. Pharmacological profile of nociceptin/orphanin FQ receptors. *Clin Exp Pharmacol Physiol* 29(3):223-228, 2002
53. **Rizzi A**, Rizzi D, Marzola G, Regoli D, Larsen BD, Petersen JS, Calo' G. Pharmacological characterization of the novel nociceptin/orphanin FQ receptor ligand, ZP120: in vitro and in vivo studies in mice. *Br J Pharmacol* 137(3):369-374, 2002.
54. **Rizzi A**, Salis MB, Ciccocioppo R, Marzola G, Bigoni R, Guerrini R, Massi M, Madeddu P, Salvadori S, Regoli D, and Calo' G. Pharmacological characterization of [(pX)Phe4]nociceptin(1-13)NH<sub>2</sub> analogues: II) in vivo studies. *NS Archives of Pharmacology*, 365: 450-456, 2002
55. Marti M, Mela F, Veronesi C, Guerrini R, Salvadori S, Federici M, Mercuri NB, **Rizzi A**, Franchi G, Beani L, Bianchi C, and Morari M. Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior. *J Neurosci.* 28;24(30):6659-6666, 2004
56. Vergura R, Camarda V, **Rizzi A**, Spagnol M, Guerrini R, Calo' G, Salvadori S, and Regoli D. Urotensin II stimulates plasma extravasation in mice via UT receptor activation. *NS Archives of Pharmacology*, 370(5): 347-352, 2004

57. Carrà G, **Rizzi A**, Guerrini R, Barnes TA, McDonald J, Hebbes C, Mela F, Kenigs VA, Marzola G, Rizzi D, Gavioli E, Zucchini S, Regoli D, Morari M, Salvadori S, Rowbotham JD, Lambert DG, Kapusta DR, and Calo' G. [(pF)Phe<sup>4</sup>,Arg<sup>14</sup>,Lys<sup>15</sup>]N/OFQ-NH<sub>2</sub> (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor. *J Pharmacol Exp Ther*, 312: 1114-1123, 2004
58. Girolamo Calo', Guerrini R, **Rizzi A**, Salvadori S, Burmeister M, Kapusta DR, Lambert DG, and Regoli D. UFP-101, a peptide antagonist selective for the nociceptin / orphanin FQ receptor. *CNS Drug Review*, 11 (2): 97-112, 2005.
59. Guerrini Remo, Camarda V, Marzola E, Arduin M, Calo' G, Spagnol M, **Rizzi A**, Salvadori S, and regoli D. Structure-activity relationship study on human urotensin II. *J Peptide Sci*, 11: 85-90, 2005.
60. **Rizzi A**, Nazzaro C, Marzola G, Zucchini S, Trapella C, Guerrini R, Zeilhofer HU, Regoli D, and Calo' G. Endogenous nociceptin/orphanin FQ signalling produces opposite spinal antinociceptive and supraspinal pronociceptive effects in the mouse formalin test: pharmacological and genetic evidences. *Pain*, 124:100-108, 2006.
61. Özge G, **Rizzi A**, Baldisserotto A, Guerrini R, Spagnolo B, Gavioli EC, Kocsis L, Magyar A, Benyhe S, Borsoni A and Calo' G. In vitro and in vivo pharmacological characterization of the nociceptin/orphanin FQ receptor ligand Ac-RYYRIK-ol. *Eur. J. Pharmacol*, 539:39-48, 2006.
62. Roth AL, Marzola E, **Rizzi A**, Arduin M, Trapella C, Corti C, Vergura R, Martinelli P, Salvadori S, Regoli D, Corsi M, Cavanni P, Calo G, Guerrini R. Structure-activity studies on neuropeptide S: identification of the amino acid residues crucial for receptor activation. *J Biol Chem* 281:20809-20816, 2006.
63. **Rizzi A**, Spagnolo B, Wainford RD, Fischetti C, Guerrini R, Marzola G, Baldisserotto A, Salvadori S, Regoli D, Kapusta DR, Calo G. In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor. *Peptides* 28(6):1240-1251, 2007.
64. Gavioli EC, **Rizzi A**, Marzola G, Zucchini S, Regoli D, Calo' G. Altered anxiety-related behavior in nociceptin/orphanin FQ receptor gene knockout mice. *Peptides* 28(6):1229-39, 2007.
65. Spagnolo B, Carrà G, Fantin M, Fischetti C, Hebbes C, McDonald J, Barnes TA, **Rizzi A**, Trapella C, Fanton G, Morari M, Lambert DG, Regoli D, Calò G. Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vitro studies. *J Pharmacol Exp Ther*. 321(3):961-7, 2007.
66. **Rizzi A**, Gavioli EC, Marzola G, Spagnolo B, Zucchini S, Ciccocioppo R, Trapella C, Regoli D, Calò G. Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vivo studies. *J Pharmacol Exp Ther*. 321(3):968-74, 2007.
67. Nazzaro C, **Rizzi A**, Salvadori S, Guerrini R, Regoli D, Zeilhofer HU, Calo G. UFP-101 antagonizes the spinal antinociceptive effects of nociceptin/orphanin FQ: behavioral and electrophysiological studies in mice. *Peptides*. 28(3):663-9, 2007.
68. Camarda V, Trapella C, Calo G, Guerrini R, **Rizzi A**, Ruzza C, Fiorini S, Marzola E, Reinscheid RK, Regoli D, Salvadori S. Synthesis and biological activity of human neuropeptide S analogues modified in position 2. *J Med Chem*. 51(3):655-658, 2008.
69. **Rizzi A**, Vergura R, Marzola G, Ruzza C, Guerrini R, Salvadori S, Regoli D, Calo G. Neuropeptide S is a stimulatory anxiolytic agent: a behavioural study in mice. *Br J Pharmacol*. 154(2):471-479, 2008.
70. Vitale G, Filaferro M, Ruggieri V, Pennella S, Frigeri C, **Rizzi A**, Guerrini R, Calo, G. Anxiolytic-like effect of neuropeptide S in the rat defensive burying. *Peptides*. 29:2286-2291, 2008
71. Fischetti C, **Rizzi A**, Gavioli EC, Marzola G, Trapella C, Guerrini R, Petersen JS, Calo' G. Further studies on the pharmacological features of the nociceptin/orphanin FQ receptor ligands ZP120. *Peptides*. 30, 248-255, 2009.
72. Camarda V, **Rizzi A**, Ruzza C, Zucchini S, Marzola G, Marzola E, Guerrini R, Salvadori S, Reinscheid RK, Regoli D, Calo G. In vitro and in vivo pharmacological characterization of the neuropeptides S receptor antagonist [D-Cys(tBu)<sup>5</sup>]NPS. *J Pharmacol Exp Ther*. 328, 549-555, 2009

73. Guerrini R, Camarda V, Trapella C, Calo G, **Rizzi A**, Ruzza C, Fiorini S, Marzola E, Reinscheid RK, Regoli D and Salvadori S Synthesis and biological activity of human neuropeptide S analogues modified in position 5: identification of potent and pure neuropeptide S receptor antagonists. *J Med Chem.* 52: 524-529, 2009.
74. Fischetti C, Camarda V, **Rizzi A**, Pela' M, Trapella C, Guerrini R, McDonald J, Lambert DG, Salvadori S, Regoli D, Calo G. Pharmacological characterization of the nociceptin/orphanin FQ non peptide antagonist Compound 24. *Eur J Pharmacol* 614: 50-57, 2009.
75. Guerrini R, Camarda V, Trapella C, Calo' G, **Rizzi A**, Ruzza C, Fiorini S, Marzola E, Reinscheid RK, Regoli D and Salvadori S Further studies at neuropeptide S position 5: discovery of novel neuropeptide S receptor antagonists. *J Med Chem* 52:4068-4071, 2009.
76. Ruzza C, **Rizzi A**, Trapella C, Pela M, Camarda V, Ruggieri V, Filafarro M, Cifani C, Reinscheid RK, Vitale G, Ciccocioppo R, Salvadori S, Guerrini R and Calo G. Further studies on the pharmacological profile of the neuropeptide S receptor antagonist SHA 68. *Peptides* 31:915-925, 2010
77. Guerrini R, Salvadori S, **Rizzi A**, Regoli D and Calo G. Neuropeptide S receptor ligands. *Med Res Rev.* 30: 751-777, 2010.
78. **Rizzi A**, Molinari S, Marti M, Marzola G, Calo G. Nociceptin/orphanin FQ receptor knockout rats: in vitro and in vivo studies. *Neuropharmacology* 60: 572-579, 2011.
79. Calo G, **Rizzi A**, Cifani C, Micioni Di Bonaventura MV, Regoli D, Massi M, Salvadori S, Lambert DG and Guerrini R. UFP-112 a potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor. *CNS Neuroscience & Therapeutics* 17: 178-198, 2011.
80. Ruzza C, Pulga A, **Rizzi A**, Marzola G, Guerrini R. and Calo G. Behavioural phenotypic characterization of CD-1 mice lacking the neuropeptide S receptor. *Neuropharmacology.* **62**, 1999-2009, 2012.
81. Ruzza, C., **Rizzi, A.**, Camarda, V., Pulga, A., Marzola, G., Filafarro, M., Novi, C., Ruggieri, V., Marzola, E., Vitale, G., Salvadori, S., Guerrini, R. & Calo, G. [tBu-D-Gly5]NPS, a pure and potent antagonist of the neuropeptide S receptor: in vitro and in vivo studies. *Peptides.* 34, 404-411, 2012.
82. **Rizzi, A**, Campi B, Camarda V, Molinari S, Cantoreggi S, Regoli D, Pietra C, and Calo, G. In vitro and in vivo pharmacological characterization of the novel NK(1) receptor selective antagonist Netupitant. *Peptides.* **37**, 86-97, 2012.
83. Pulga A, Ruzza C, **Rizzi A**, Guerrini R, Calo G. Anxiolytic- and panicolytic-like effects of Neuropeptide S in the mouse elevated T-maze. *Eur J Neurosci* 36: 3531-3537, 2012.
84. Molinari, S., Camarda, V., **Rizzi, A.**, Marzola, G., Salvadori, S., Marzola, E., Molinari, P., McDonald, J., Ko, M.C., Lambert, D.G., Calo, G. & Guerrini, R. [Dmt1]N/OFQ(1-13)-NH2: a potent nociceptin/orphanin FQ and opioid receptor universal agonist. *Br J Pharmacol.* **168**, 151-162, 2013.
85. Camarda V, Ruzza C, **Rizzi A**, Trapella C, Guerrini R, Reinscheid RK and Calo G. In vitro and in vivo pharmacological characterization of the novel neuropeptide S receptor ligands QA1 and PII. *Peptides.* **48**, 27-35, 2013.
86. Guerrini R, Marzola E, Trapella C, Pela M, Molinari S, Cerlesi MC, Malfacini D, **Rizzi A**, Salvadori S, Calo G. A novel and facile synthesis of tetra branched derivatives of nociceptin/orphanin FQ. *Bioorg Med Chem.* **22**:3703-3712, 2014.
87. **Rizzi A**, Malfacini D, Cerlesi MC, Ruzza C, Marzola E, Bird MF, Rowbotham DJ, Salvadori S, Guerrini R, Lambert DG, Calo G. In vitro and in vivo pharmacological characterization of nociceptin/orphanin FQ tetrabranched derivatives. *Br J Pharmacol.* **171**:4138-4153, 2014.
88. Ruzza C, **Rizzi A**, Malfacini D, Cerlesi MC, Ferrari F, Marzola E, Ambrosio C, Gro C, Severo S, Costa T, Calo G, Guerrini R. Pharmacological characterization of tachykinin tetrabranched derivatives. *Br J Pharmacol.* **171**:4125-4137, 2014.
89. Micheli L, Di Cesare Mannelli L, Guerrini R, Trapella C, Zanardelli M, Ciccocioppo R, **Rizzi A**, Ghelardini C, Calò G. Acute and subchronic antinociceptive effects of nociceptin/orphanin FQ receptor agonists infused by intrathecal route in rats. *Eur J Pharmacol.* **754**:73-81. 2015
90. Ruzza C, **Rizzi A**, Malfacini D, Pulga A, Pacifico S, Salvadori S, Trapella C, Reinscheid RK, Calo G, Guerrini R. In vitro and in vivo pharmacological characterization of a neuropeptide S tetrabranched derivative. *Pharmacol Res Perspect.* doi: 10.1002/prp2.108, 2015.
91. Ruzza C, **Rizzi A**, Malfacini D, Molinari S, Giuliano C, Lovati E, Pietra C, Calo G. In vitro and in vivo pharmacological characterization of Pronetupitant, a prodrug of the neurokinin 1 receptor antagonist Netupitant. *Peptides* **69**: 26-32, 2015.



92. **Rizzi A**, Sukhtankar DD, Ding D, Hayashida K, Ruzza C, Guerrini R, Calò G and Ko Mc. Spinal antinociceptive effects of the novel NOP receptor agonist PWT2-nociceptin/orphanin FQ in mice and monkeys. *Br J Pharmacol* **172**:3661-3670, 2015,
93. Micheli L, Di Cesare Mannelli L, **Rizzi A**, Guerrini R, Trapella C, Calò G, Ghelardini C. Intrathecal administration of nociceptin/orphanin FQ receptor agonists in rats: A strategy to relieve chemotherapy-induced neuropathic hypersensitivity. *Eur J Pharmacol.* 766:155-62, 2015.

### Book Chapter

Calò G, Rizzi A, Regoli D. Pharmacology of nociceptin receptors. In Peptidergic G protein-coupled receptors: from basic research to clinical applications. IOS Press, Van Diemenstraat 94, 1013 CN Amsterdam, Netherlands. NATO Science Series. Edited by Pierangelo Geppetti, Werner Muller-Esterl, Domenico Regoli. 1999

### Society membership:

Società Italiana di Farmacologia (2000-); European Neuropeptide Club (1997-)

### Research grants

Grants to Anna Rizzi as PI

- 2014 - Fondo per le Necessità di base della ricerca 2014 – “Roles of NOP and NOP/MOP agonists on the activation of the sensory neurons mediate by the TRP channels” University of Ferrara, Italy.
- 1999 – “B1 and PAR-2: inducible receptors expressed by the endothelial cells of the human umbilical vein and of the microcirculation. Studies of the mechanisms of up-regulation and expression of these inducible receptors”, University of Ferrara, Italy.
- 2000 - “In vitro and in vivo studies of the effects of the human urotensin II in different species, human included”, National Council of the Research, CNR-Agenzia 2000, code CNRG00C437
- 2001 – “Role of the hemokinin, a new member of the tachykinins family, in inflammatory processes: in vitro and in vivo studies”, University of Ferrara, .

In 1997, A Rizzi won a bursary from the National Council of the Research (CNR): International exchange “Short-term mobility”, CNR Prot. 055366 for her stage as Research Fellow at the UCSF in the Prof. N. Bunnett laboratory, Department of Physiology, University of San Francisco, USA.

Since 1999 A Rizzi participated as co-investigators in different grants received from different institutions at local (University of Ferrara, 60% grant from 1999 to 2011), National (Cofin 1999, 2002; 2004; 2006; Firb 2001-03), European (2001 CRUI/British Council, partner prof D Lambert, Leicester, UK; 2003 Vigoni CRUI/DAAD, partner Prof H Zeilhofer, Erlangen, D) and international (2003-2008 NIH grant RO1HL71212, partner prof D Kapusta, New Orleans, US; 2003-2004

International Association for the Study of Pain, partner prof D Lambert, Leicester, UK) levels.

FAR (Research Funds of the University of Ferrara) 1996: pharmacology of vasoactive peptides, 1y, collaborator (PI D Regoli)  
FAR 1997: pharmacology of vasoactive peptides 1y collaborator (PI D Regoli).  
FAR 1998: pharmacology of vasoactive peptides 1y collaborator (PI D Regoli)  
FAR 1999: pharmacology of N/OFQ 1y collaborator (PI G Calo)  
PRIN 1999 9905091432\_001: pharmacology of the N/OFQ - NOP receptor system 2y collaborator (PI D Regoli)  
FAR 2000: pharmacology of N/OFQ 1y collaborator (PI G Calo)  
FAR 2001: pharmacology of N/OFQ 1y collaborator (PI G Calo)  
CRUI/British Council IT/UK 2001: cellular actions of NOP ligands (partner DG Lambert, Leicester, UK) 2y collaborator (PI G Calo)  
FP6-2002-MOBILITY-7: Nociceptin/orphanin FQ-NOP receptor signalling and mood regulation: behavioural, pharmacological and neurochemical studies (MOODNOP) 2y collaborator (PI G Calo, PI of the host institution)  
FAR 2002: pharmacology of N/OFQ 1y collaborator (PI G Calo)  
PRIN 2002 2002058325\_001: pharmacology and neurobiology of NOP ligands, 2y collaborator (PI D Regoli)  
FIRB 2001 RBAU01CCSE\_001: novel ligands for the NOP receptor, 3y collaborator (PI D Regoli)  
NIH grant 2003 RO1HL71212: cardiovascular and renal effects of NOP ligands, 5y collaborator (partner and PI D Kapusta, New Orleans, US)  
FAR 2003: pharmacology of N/OFQ, 1y collaborator (PI G Calo)  
FAR 2004: pharmacology of N/OFQ and NPS, 1y collaborator (PI G Calo)  
PRIN 2004 2004055475\_001: pharmacology and biological actions of NOP ligands, 2y collaborator (PI D Regoli)  
FAR 2005: pharmacology of N/OFQ and NPS 1y collaborator (PI G Calo)  
FAR 2006: pharmacology of N/OFQ and NPS 1y collaborator (PI G Calo)  
PRIN 2006: Il sistema neuropeptide S - recettore NPSR: identificazione di nuovi ligandi e studio delle attivita' biologiche in vitro ed in vivo, 2 y, collaborator (PI G Calo)  
FAR 2007: pharmacology of N/OFQ and NPS 1y collaborator (PI G Calo)  
IT/HU 2007: novel ligands for opioid and NOP receptors (partner S Behnje, Szeged, HU) 3y PI.  
FAR 2008: pharmacology of N/OFQ and NPS 1y collaborator (PI G Calo)  
FAR 2009: pharmacology of N/OFQ and NPS 1y collaborator (PI G Calo)  
Neuroscience grant (Fondazione Compagnia S. Paolo) 2009: pharmacology and neurobiology of NPS 3y collaborator (PI of the UniFE research unit G Calo)  
FAR 2010: pharmacology of N/OFQ and NPS 1y collaborator (PI G Calo)  
FIRB 2010 RBFR109SBM\_001: mixed MOP/NOP agonists as innovative analgesics 3y collaborator (PI C Trapella)  
FAR 2011: pharmacology of N/OFQ and NPS 1y collaborator (PI G Calo)  
FAR 2012: pharmacology of N/OFQ and NPS 1y collaborator (PI G Calo)  
FAR 2013-2014: pharmacology of N/OFQ and NPS 1y collaborator (PI G Calo)

## **Technology transfer**

During the period 1995-2000 A Rizzi contributed, as D Regoli and G calo collaborator, to the development of several industrial research projects in collaborations with the following companies: Italfarmaco (1994/95) novel antagonists of Y1 and B1 receptors, Hoest (1996) novel KATP blockers, Menarini (1997/98) B2 receptor antagonists, Schering-plough (1999/2000) NOP receptor agonists, Aventis (2000) UT receptor ligands; Zealand Pharma (2001) pharmacological characterization of ZP120, GSK (2006) central effects of U-II, Allergan (2007-09) peripheral actions of NOP ligands, Helsinn (2009) pharmacological characterization of Netupitant, Allergan (2010/11) studies on retargeted toxins. Helsinn (2012) pharmacological characterization of proNetupitant. Helsinn (2013/14) pharmacological profile of pronetupitant. Allergan (2013/14) further studies on retargeted toxins.

From Genuary 2007 to December 2012 A Rizzi was the Chief Executive Officer of the spin off UFPeptides s.r.l.

UFPeptides provides products and services to pharma companies. UFPeptides activities are focused to the identification and development of molecules interacting with G-protein coupled receptors; these proteins regulate several important biological functions and are implicated in a large variety of human diseases. UFPeptides collaborated with pharma companies for the development of research projects (2004-09), performed a proprietary research project partially funded by a PRRIITT grant (FSE funds, 2006-07), and made an agreement with two companies for the preclinical development of the agonopin (NOP agonists for urinary incontinence) project (2006). For this project an exclusive option license agreement has been signed by UFPeptides and Recordati in 2009 and a license agreement in 2011. The Phase I study of the agonopin project started in May 2014.

### **Teaching Activities**

Incarichi Ufficiali di insegnamento

Culture della materia Settore BIO/14, Farmacologia dal 1999 ad oggi  
Corso di Farmacologia, Corso di Laurea per Dietista, Facoltà di Medicina e Chirurgia, Università di Ferrara da Ottobre 2012 ad oggi.

Corso di Farmacologia, Corso di Laurea per Igienisti Dentali, Facoltà di Medicina e Chirurgia, Università di Ferrara da Ottobre 2012 ad oggi.

Esercitazioni per corsi ufficiali. Corsi di Farmacologia per studenti di Biotecnologie (Docente incaricato: Dr Silvia Zucchini). Università di Ferrara. Dal 2008 ad oggi.

Lezioni per corsi ufficiali. Corsi di Farmacologia generale e speciale per studenti di Odontoiatria, Igiene Dentale, e Dietistica (Docente incaricato: Dr Girolamo Calò). Università di Ferrara. Dal 2008 al 2012.

Partecipazione a commissioni di esami di profitto. Esami di Farmacologia generale e speciale per studenti di Odontoiatria (Docente incaricato: Dr Girolamo Calò). Università di Ferrara. Dal 2008 ad oggi.

Membro della commissione di Laurea in Medicina e Chirurgia e controrelatore di tesi da Marzo 2015. Università di Ferrara.

Supervisione attività di ricerca per tesi di laurea. Corsi di Laurea in Farmacia, Chimica e Tecnologie Farmaceutiche, e Scienze Biologiche, Odontoiatria. Università di Ferrara. Dal 1999 ad oggi.

Supervisione attività di ricerca dei dottorandi. Dottorato di Ricerca in Farmacologia Cellulare e Molecolare. Università di Ferrara. Dal 2000 ad oggi.